A Tier 3 Sponsor with active clinical investigations and multiple active, existing Investigational New Drug Applications (INDs) was unhappy with their current vendor’s support. The Sponsor selected Certara as its new vendor for Lifecycle Maintenance (LCM) of their INDs. It was important to the Sponsor team that they received better responsiveness and minimal disruption of activities during transition in the new partnership.
The Certara team was ready to assume publishing of the Sponsor’s sequences within days of the signed contract. The Sponsor was overall delighted by the smooth onboarding experience and engagement by the Certara team and immediately benefitted from our industry-leading turnaround times for routine IND submissions.
联系我们